Officials with the FDA have granted approval to ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of relapsing multiple sclerosis.
On December 23, 2019, the FDA approved ubrogepant for the acute treatment of migraine with and without aura in adult patients.
Approximately 1 million individuals are living with multiple sclerosis in the United States, according to the National MS Society.
Rimegepant (Nurtec ODT, Biohaven),a fast-acting orally disintegrating tablet, delivers quick and sustained efficacy for patients with migraine.
Eptinezumab-jjmr (Vyepti, Lundbeck) decreased mean monthly migraine days in adult patients in 2 phase 3 clinical trials.
Genentech announced new 1-year data from the SUNFISH trial evaluating risdiplam in spinal muscular atrophy.
Delayed-release oral capsules for various forms of the disease.
Monoclonal antibody for autoimmune and neurodegenerative disorders.